Association of ApoE and HDL-C with cardiovascular and cerebrovascular disease: Potential benefits of LDL-apheresis therapy

Future Lipidology

Volumn 4, Issue 3, 2009, Pages 311-329

  Moriarty, Patrick M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; ApoE; ApoE4; Cardiovascular disease; Cerebral vascular disease; Familial hypercholesterolemia; HDL C; Inflammation; LDL apheresis; Serum amyloid A

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROBUCOL; RESIN; SERUM AMYLOID A; SERUM AMYLOID P; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

APHERESIS; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; BLOOD RHEOLOGY; BLOOD VISCOSITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; ENCEPHALITIS; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; RECEPTOR BINDING; REVIEW;

EID: 67249090363     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.21     Document Type: Review

References (251)

1. Davignon J: Apolipoprotein E and atherosclerosis: beyond lipid effect. Arterioscler. Thromb. Vasc. Biol. 25 (2), 267-269 (2005).
2. Mahley RW, Rall SC Jr: Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1, 507-537 (2000).
3. Hime NJ, Drew KJ, Hahn C et al.: Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner. Biochemistry 43 (38), 12306-12314 (2004).
4. Cohn JS, Tremblay M, Amiot M et al.: Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 16 (1),149-159 (1996).
5. Settasatian N, Barter PJ, Rye KA: Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. J. Lipid Res. 49 (1), 115-126 (2008).
6. Haffner SM, Stern MP, Miettinen H et al.: Apolipoprotein E polymorphism and LDL-C size in a biethnic population. Arterioscler. Thromb. Vasc. Biol. 16 (9), 1184-1188 (1996).
7. Wilson PW: Relation of high-density lipoprotein subfractions and apolipoprotein E isoforms to coronary disease. Clin. Chem. 41 (1), 165-169 (1995).
8. Morrow JA, Hatters DM, Lu B et al.: Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J. Biol. Chem. 277 (52), 50380-50385 (2002).
9. Walden CC, Hegele RA: Apolipoprotein E in hyperlipidemia. Ann. Intern. Med. 120 (12), 1026-1036 (1994).
10. Zannis VI, Breslow JL, Utermann G et al.: Proposed nomenclature of ApoE isoproteins, ApoE genotypes, and phenotypes. J. Lipid Res. 23 (6), 911-914 (1982).
11. Dong LM, Wilson C, Wardell MR et al.: Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J. Biol. Chem. 269 (35),22358-22365 (1994).
12. Steinmetz A, Jakobs C, Motzny S et al.: Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis 9 (3), 405-411 (1989).
13. Small BJ, Rosnick CB, Fratiglioni L et al.: Apolipoprotein E and cognitive performance: a meta-analysis. Psychol. Aging 19 (4), 592-600 (2004).
14. Cedazo-Minguez A: Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med. 11 (6), 1227-1238 (2007).
15. Hopkins PC, Huang Y, McGuire JG et al.: Evidence for differential effects of ApoE3 and ApoE4 on HDL-C metabolism. J. Lipid Res. 43 (11), 1881-1889 (2002).
16. Luc G, Bard JM, Arveiler D et al.: Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler. Thromb. 14 (9), 1412-1419 (1994).
17. Wilson PW, Myers RH, Larson MG et al.: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 272 (21), 1666-1671 (1994).
18. Wilson PW, Schaefer EJ, Larson MG et al.: Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler. Thromb. Vasc. Biol. 16 (10), 1250-1255 (1996).
19. Gerdes LU, Gerdes C, Kervinen K et al.: The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian Simvastatin Survival Study. Circulation 101 (12), 1366-1371 (2000).
20. de Knijff P, Kaptein A, Boomsma D et al.: Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a). Atherosclerosis 90 (2-3), 169-174 (1991).
21. Miyata M, Smith JD: Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat. Genet. 14 (1), 55-61 (1996).
22. Kohlmeier M, Salomon A, Saupe J et al.: Transport of vitamin K to bone in humans. J. Nutr. 126 (Suppl. 4), S1192-S1196 (1996).
23. Stiefel P, Montilla C, Muniz-Grijalvo O et al.: Apolipoprotein E gene polymorphism is related to metabolic abnormalities, but does not influence erythrocyte membrane lipid composition or sodium-lithium counter-transport activity in essential hypertension. Metabolism 50 (2), 157-160 (2001).
24. Kahri J, Soro-Paavonen A, Ehnholm C et al.: ApoE polymorphism is associated with C-reactive protein in low-HDL-C family members and in normolipidemic subjects. Mediators Inflamm. 2006 (3), 12587 (2006).
25. Christidis DS, Liberopoulos EN, Kakafika AI et al.: The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J. Cardiovasc. Pharmacol. Ther. 11 (3), 211-221 (2006).
26. Ordovas JM, Mooser V: The ApoE locus and the pharmacogenetics of lipid response. Curr. Opin. Lipidol. 13 (2), 113-117 (2002).
27. Perova NV, Metelskaya VA, Bubnova MG et al.: Association of Apo E polymorphism with nutritional and drug-induced changes in lipoproteins. Eur. J. Lab. Med. 1, 6 (1997).
28. Yamada M: Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients. J. Atheroscler. Thromb. 4 (1), 40-44 (1997).
29. Haddy N, De Bacquer D, Chemaly MM et al.: The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. Eur. J. Hum. Genet. 10 (12), 841-850 (2002).
30. Mooijaart SP, Berbee JF, van Heemst D et al.: ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med. 3 (6), e176 (2006).
31. van den Elzen P, Garg S, Leon L et al.: Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437 (7060), 906-910 (2005).
32. Reilly M, Rader DJ: Apolipoprotein E and coronary disease: a puzzling paradox. PLoS Med. 3(6),e258 (2006).
33. van Vliet P, Mooijaart SP, de Craen AJ et al.: Plasma levels of apolipoprotein E and risk of stroke in old age. Ann. NY Acad. Sci. 1100, 140-147 (2007).
34. Hahne S, Nordstedt C, Ahlin A et al.: Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. Neurosci. Lett. 224(2),99-102 (1997).
35. Taddei K, Clarnette R, Gandy SE et al.: Increased plasma apolipoprotein E (ApoE) levels in Alzheimer's disease. Neurosci. Lett. 223(1),29-32 (1997).
36. Merched A, Blain H, Visvikis S et al.: Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. J. Neurol. Sci. 145(1), 33-39 (1997).
37. Slooter AJ, de Knijff P, Hofman A et al.: Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci. Lett. 248(1),21-24 (1998).
38. Scacchi R, Gambina G, Ruggeri M et al.: Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci. Lett. 259(1),33-36 (1999).
39. Rensen PC, Schiffelers RM, Versluis AJ et al.: Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol. Pharmacol. 52(3), 445-455 (1997).
40. Angelin B, Holmquist L, Leijd B et al.: Bile acid metabolism in familial dysbetalipoproteinaemia: studies in subjects with the apolipoprotein E-2/2 phenotype. Eur. J. Clin. Invest. 20(2),143-149 (1990).
41. Smit M, de Knijff P, Rosseneu M et al.: Apolipoprotein E polymorphism in The Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum. Genet. 80(3), 287-292 (1988).
42. Utermann G, Pruin N, Steinmetz A: Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. Clin. Genet. 15(1),63-72 (1979).
43. Mamotte CD, Sturm M, Foo JI et al.: Comparison of the LDL-receptor binding of VLDL-C and LDL-C from ApoE4 and ApoE3 homozygotes. Am. J. Physiol. 276(3 Pt 1), E553-E557 (1999).
44. Altenburg M, Arbones-Mainar J, Johnson L et al.: Human LDL-C receptor enhances sequestration of ApoE4 and VLDL-C remnants on the surface of hepatocytes but not their internalization in mice. Arterioscler. Thromb. Vasc. Biol. 28(6), 1104-1110 (2008).
45. Gregg RE, Zech LA, Schaefer EJ et al.: Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78(3), 815-821 (1986).
46. Chou CY, Jen WP, Hsieh YH et al.: Structural and functional variations in human apolipoprotein E3 and E4. J. Biol. Chem. 281(19), 13333-13344 (2006).
47. Heeren J, Grewal T, Laatsch A et al.: Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J. Biol. Chem. 279(53), 55483-55492 (2004).
48. Heeren J, Beisiegel U, Grewal T: Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26(3), 442-448 (2006).
49. Gordon DJ, Probstfield JL, Garrison RJ et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1), 8-15 (1989).
50. Toth PP: High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am. J. Cardiol. 96(9A), K50-K58; discussion K34-K35 (2005).
51. Castelli WP, Garrison RJ, Wilson PW et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256(20), 2835-2838 (1986).
52. Brown BG, Zhao XQ, Chait A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345(22), 1583-1592 (2001).
53. Robins SJ, Collins D, Wittes JT et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285(12), 1585-1591 (2001).
54. Sacks FM, Tonkin AM, Craven T et al.: Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 105(12), 1424-1428 (2002).
55. Assmann G, Gotto AM Jr: HDL-C cholesterol and protective factors in atherosclerosis. Circulation 109(23 Suppl. 1), III8-III14 (2004).
56. Ansell BJ, Fonarow GC, Fogelman AM: High-density lipoprotein: is it always atheroprotective? Curr. Atheroscler. Rep. 8(5), 405-411 (2006).
57. Ansell BJ, Fonarow GC, Fogelman AM: The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol. 18(4), 427-434 (2007).
58. deGoma EM, Leeper NJ, Heidenreich PA: Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J. Am. Coll. Cardiol. 51(1),49-55 (2008).
59. van der Steeg WA, Holme I, Boekholdt SM et al.: High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 51(6), 634-642 (2008).
60. Tall AR: Plasma cholesteryl ester transfer protein. J. Lipid Res. 34(8), 1255-1274 (1993).
61. Hirano K, Yamashita S, Matsuzawa Y: Pros and cons of inhibiting cholesteryl ester transfer protein. Curr. Opin. Lipidol. 11(6), 589-596 (2000).
62. Barkowski RS, Frishman WH: HDL-C metabolism and CETP inhibition. Cardiol. Rev. 16(3), 154-162 (2008).
63. Matsuura F, Wang N, Chen W et al.: HDL-C from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an ApoE- and ABCG1-dependent pathway. J. Clin. Invest. 116(5), 1435-1442 (2006).
64. Zhong S, Sharp DS, Grove JS et al.: Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL-C levels. J. Clin. Invest. 97(12), 2917-2923 (1996).
65. Joy T, Hegele RA: Is raising HDL-C a futile strategy for atheroprotection? Nat. Rev. Drug Discov. 7(2), 143-155 (2008).
66. Levy Y: High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench. Cardiovasc. Res. 77(4), 614-615 (2008).
67. Barter PJ, Caulfield M, Eriksson M et al.: Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109-2122 (2007).
68. Yamashita S, Maruyama T, Hirano K et al.: Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis 152(2), 271-285 (2000).
69. Ishigami M, Yamashita S, Sakai N et al.: Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J. Biochem. 116(2), 257-262 (1994).
70. Brown ML, Inazu A, Hesler CB et al.: Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342 (6248), 448-451 (1989).
71. Keidar S, Ostlund RE Jr, Schonfeld G: Apolipoprotein E-rich HDL-C in patients with homozygous familial hypercholesterolemia. Atherosclerosis 84(2-3), 155-163 (1990).
72. Oram JF, Lawn RM: ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. 42(8), 1173-1179 (2001).
73. Furbee JW Jr, Francone O, Parks JS: In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL-C receptor and apolipoprotein E knockout mice. J. Lipid Res. 43(3), 428-437 (2002).
74. von Eckardstein A, Nofer JR, Assmann G: High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21(1),13-27 (2001).
75. Schmitz G, Assmann G: Isolation of human serum HDL1 by zonal ultracentrifugation. J. Lipid Res. 23(6), 903-910 (1982).
76. Ashby DT, Rye KA, Clay MA et al.: Factors influencing the ability of HDL-C to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18(9), 1450-1455 (1998).
77. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL-C particles exert potent protection of atherogenic LDL-C against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23(10),1881-1888 (2003).
78. Thuahnai ST, Lund-Katz S, Dhanasekaran P et al.: Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol. Influence of high density lipoprotein size and structure. J. Biol. Chem. 279(13),12448-12455 (2004).
79. Barter P, Kastelein J, Nunn A et al.: High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168(2), 195-211 (2003).
80. Morgan J, Carey C, Lincoff A et al.: High-density lipoprotein subfractions and risk of coronary artery disease. Curr. Atheroscler. Rep. 6(5), 359-365 (2004).
81. Vaisar T, Pennathur S, Green PS et al.: Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117(3), 746-756 (2007).
82. Meyers CD, Kashyap ML: Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr. Opin. Cardiol. 19(4),366-373 (2004).
83. Sharp DS, Burchfiel CM, Rodriguez BL et al.: Apolipoprotein A-1 predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japanese-Americans. Int. J. Clin. Lab. Res. 30(1), 39-48 (2000).
84. Eriksson M, Carlson LA, Miettinen TA et al.: Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 100(6), 594-598 (1999).
85. Sirtori CR, Calabresi L, Franceschini G: Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis 142(1), 29-40 (1999).
86. Brousseau ME, Schaefer EJ, Wolfe ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL-C cholesterol. N. Engl. J. Med. 350(15), 1505-1515 (2004).
87. Elisaf M: Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18(5), 269-276 (2002).
88. Guerin M, Lassel TS, Le Goff W et al.: Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL-C to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 20(1),189-197 (2000).
89. Carrilho AJ, Medina WL, Nakandakare ER et al.: Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. Clin. Pharmacol. Ther. 62(1),82-88 (1997).
90. Thomas TR, Smith BK, Donahue OM et al.: Effects of omega-3 fatty acid supplementation and exercise on low-density lipoprotein and high-density lipoprotein subfractions. Metabolism 53(6), 749-754 (2004).
91. Morgan JM, Capuzzi DM, Baksh RI et al.: Effects of extended-release niacin on lipoprotein subclass distribution. Am. J. Cardiol. 91(12), 1432-1436 (2003).
92. Syvanne M, Nieminen MS, Frick MH et al.: Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL-C cholesterol. Circulation 98(19), 1993-1999 (1998).
93. Otvos JD, Collins D, Freedman DS et al.: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113(12), 1556-1563 (2006).
94. Asztalos BF, Batista M, Horvath KV et al.: Change in α1 HDL-C concentration predicts progression in coronary artery stenosis. Arterioscler. Thromb. Vasc. Biol. 23(5), 847-852 (2003).
95. Koo C, Innerarity TL, Mahley RW: Obligatory role of cholesterol and apolipoprotein E in the formation of large cholesterol-enriched and receptor-active high density lipoproteins. J. Biol. Chem. 260(22), 11934-11943 (1985).
96. Mahley RW, Innerarity TL, Weisgraber KH et al.: Canine hyperlipoproteinemia and atherosclerosis. Accumulation of lipid by aortic medial cells in vivo and in vitro. Am. J. Pathol. 87(1),205-226 (1977).
97. Mahley RW, Innerarity TL, Bersot TP et al.: Alterations in human high-density lipoproteins, with or without increased plasma-cholesterol, induced by diets high in cholesterol. Lancet 2(8094), 807-809 (1978).
98. McGill HC Jr, McMahan CA, Kushwaha RS et al.: Dietary effects on serum lipoproteins of dyslipoproteinemic baboons with high HDL1. Arteriosclerosis 6(6), 651-663 (1986).
99. Yamashita S, Sprecher DL, Sakai N et al.: Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J. Clin. Invest. 86(3), 688-695 (1990).
100. Clark RW, Sutfin TA, Ruggeri RB et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24(3), 490-497 (2004).
101. Ha YC, Barter PJ: Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp. Biochem. Physiol. B 71(2), 265-269 (1982).
102. Innerarity TL, Mahley RW, Weisgraber KH et al.: Apoprotein (E-A-II) complex of human plasma lipoproteins. II. Receptor binding activity of a high density lipoprotein subfraction modulated by the apo(E-A-II) complex. J. Biol. Chem. 253(17), 6289-6295 (1978).
103. Davidson WS, Silva RA: Apolipoprotein structural organization in high density lipoproteins: belts, bundles, hinges and hairpins. Curr. Opin. Lipidol. 16(3), 295-300 (2005).
104. Silva RA, Hilliard GM, Li L et al.: A mass spectrometric determination of the conformation of dimeric apolipoprotein A-I in discoidal high density lipoproteins. Biochemistry 44(24), 8600-8607 (2005).
105. Mahley RW, Huang Y, Weisgraber KH: Putting cholesterol in its place: ApoE and reverse cholesterol transport. J. Clin. Invest. 116(5), 1226-1229 (2006).
106. 1 in cholesteryl ester uptake in rats. J. Lipid Res. 34(4), 571-579 (1993).
107. Esteve E, Ricart W, Fernandez-Real JM: Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin. Nutr. 24(1), 16-31 (2005).
108. Khovidhunkit W, Shigenaga JK, Moser AH et al.: Cholesterol efflux by acute-phase high density lipoprotein: role of lecithin: cholesterol acyltransferase. J. Lipid Res. 42(6), 967-975 (2001).
109. Khovidhunkit W, Duchateau PN, Medzihradszky KF et al.: Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL. Atherosclerosis 176(1), 37-44 (2004).
110. Coetzee GA, Strachan AF, van der Westhuyzen DR et al.: Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem. 261(21), 9644-9651 (1986).
111. Liuzzo G, Biasucci LM, Gallimore JR et al.: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med. 331(7), 417-424 (1994).
112. Kosuge M, Ebina T, Ishikawa T et al.: Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ. J. 71(2),186-190 (2007).
113. Cabana VG, Feng N, Reardon CA et al.: Influence of ApoA-I and ApoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J. Lipid Res. 45(2),317-325 (2004).
114. Uhlar CM, Whitehead AS: Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265(2), 501-523 (1999).
115. Clifton PM, Mackinnon AM, Barter PJ: Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J. Lipid Res. 26(12), 1389-1398 (1985).
116. Miida T, Yamada T, Yamadera T et al.: Serum amyloid A protein generates pre β 1 high-density lipoprotein from α-migrating high-density lipoprotein. Biochemistry 38(51), 16958-16962 (1999).
117. Miida T, Nakamura Y, Inano K et al.: Pre β1 high-density lipoprotein increases in coronary artery disease. Clin. Chem. 42(12), 1992-1995 (1996).
118. Tashiro JOM, Nakamura Y, Miyazaki A et al.: Plasma preβ1-HDL-C level is elevated in unstable angina pectoris. Atherosclerosis (2008) (In press).
119. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8(1), 1-21 (1988).
120. Norata GD, Pirillo A, Catapano AL: Modified HDL: biological and physiopathological consequences. Nutr. Metab. Cardiovasc. Dis. 16(5), 371-386 (2006).
121. Navab M, Berliner JA, Subbanagounder G et al.: HDL-C and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21(4),481-488 (2001).
122. Banka CL, Yuan T, de Beer MC et al.: Serum amyloid A (SAA), influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res. 36(5), 1058-1065 (1995).
123. Kisilevsky R, Subrahmanyan L: Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab. Invest. 66(6), 778-785 (1992).
124. Quan G, Xie C, Dietschy JM et al.: Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. Brain Res. Dev. Brain Res. 146(1-2), 87-98 (2003).
125. Roheim PS, Carey M, Forte T et al.: Apolipoproteins in human cerebrospinal fluid. Proc. Natl Acad. Sci. USA 76(9), 4646-4649 (1979).
126. Pitas RE, Boyles JK, Lee SH et al.: Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262(29), 14352-14360 (1987).
127. Koch S, Donarski N, Goetze K et al.: Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 42(7), 1143-1151 (2001).
128. Guyton JR, Miller SE, Martin ME et al.: Novel large apolipoprotein E-containing lipoproteins of density 1.006-001.060 g/ml in human cerebrospinal fluid. J. Neurochem. 70(3), 1235-1240 (1998).
129. Yamauchi K, Tozuka M, Hidaka H et al.: Characterization of apolipoprotein E-containing lipoproteins in cerebrospinal fluid: effect of phenotype on the distribution of apolipoprotein E. Clin. Chem. 45(9), 1431-1438 (1999).
130. Strittmatter WJ, Bova Hill C: Molecular biology of apolipoprotein E. Curr. Opin. Lipidol. 13(2), 119-123 (2002).
131. Gong JS, Morita SY, Kobayashi M et al.: Novel action of apolipoprotein E (ApoE), ApoE isoform specifically inhibits lipid-particle-mediated cholesterol release from neurons. Mol. Neurodegener. 2,9 (2007).
132. Boyles JK, Pitas RE, Wilson E et al.: Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 76(4), 1501-1513 (1985).
133. Yamauchi K, Tozuka M, Nakabayashi T et al.: Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations. Clin. Chem. 45(4), 497-504 (1999).
134. Carlsson J, Armstrong VW, Reiber H et al.: Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid. Clin. Chim. Acta 196(2-3), 167-176 (1991).
135. Elshourbagy NA, Boguski MS, Liao WS et al.: Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc. Natl Acad. Sci. USA 82(23), 8242-8246 (1985).
136. Swanson LW, Simmons DM, Hofmann SL et al.: Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization. Proc. Natl Acad. Sci. USA 85(24), 9821-9825 (1988).
137. Irizarry M: Modulation of brain apolipoprotein E levels by the low-density lipoprotein receptor. Neurobiol. Lipids 4(2), (2005).
138. Mahley RW, Huang Y: Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of ApoE4 can modulate neuropathology. Acta Neurol. Scand. (Suppl. 185), 8-14 (2006).
139. Methia N, Andre P, Hafezi-Moghadam A et al.: ApoE deficiency compromises the blood-brain barrier especially after injury. Mol. Med. 7(12),810-815 (2001).
140. Cras P, Kawai M, Lowery D et al.: Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc. Natl Acad. Sci. USA 88(17), 7552-7556 (1991).
141. Eckert GP, Kirsch C, Leutz S et al.: Cholesterol modulates amyloid β-peptide's membrane interactions. Pharmacopsychiatry 36 (Suppl. 2), S136-S143 (2003).
142. Koudinov AR, Koudinova NV, Kumar A et al.: Biochemical characterization of Alzheimer's soluble amyloid β protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem. Biophys. Res. Commun. 223(3), 592-597 (1996).
143. Ladu MJ, Reardon C, Van Eldik L et al.: Lipoproteins in the central nervous system. Ann. NY Acad. Sci. 903, 167-175 (2000).
144. Nathan BP, Bellosta S, Sanan DA et al.: Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264(5160), 850-852 (1994).
145. Holtzman DM, Pitas RE, Kilbridge J et al.: Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl Acad. Sci. USA 92(21), 9480-9484 (1995).
146. Buttini M, Akeefe H, Lin C et al.: Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease. Neuroscience 97(2), 207-210 (2000).
147. Akiyama H, Barger S, Barnum S et al.: Inflammation and Alzheimer's disease. Neurobiol. Aging 21(3), 383-421 (2000).
148. Vasto S, Candore G, Duro G et al.: Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. Pharmacogenomics 8(12), 1735-1745 (2007).
149. Gahtan E, Overmier JB: Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive sequeli. Neurosci. Biobehav. Rev. 23(5), 615-633 (1999).
150. Liang JS, Sloane JA, Wells JM et al.: Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Neurosci. Lett. 225(2), 73-76 (1997).
151. Nybo M, Olsen H, Jeune B et al.: Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance. Dement. Geriatr. Cogn. Disord. 9(3), 126-129 (1998).
152. Flex A, Pola R, Serricchio M et al.: Polymorphisms of the macrophage inhibitory factor and C-reactive protein genes in subjects with Alzheimer's dementia. Dement. Geriatr. Cogn. Disord. 18(3-4), 261-264 (2004).
153. Kindy MS, Yu J, Guo JT et al.: Apolipoprotein serum amyloid a in Alzheimer's disease. J. Alzheimers Dis. 1(3), 155-167 (1999).
154. Urieli-Shoval S, Cohen P, Eisenberg S et al.: Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J. Histochem. Cytochem. 46(12), 1377-1384 (1998).
155. McGeer EG, Yasojima K, Schwab C et al.: The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol. Aging 22(6), 843-848 (2001).
156. Jenny NS, Arnold AM, Kuller LH et al.: Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 27(2), 352-358 (2007).
157. Kalaria RN, Kroon SN: Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer's disease. Biochem. Biophys. Res. Commun. 186(1), 461-466 (1992).
158. Miida T, Yamazaki F, Sakurai M et al.: The apolipoprotein E content of HDL-C in cerebro-spinal fluid is higher in children than in adults. Clin. Chem. 45(8 Pt 1), 1294-1296 (1999).
159. Yamauchi K, Tozuka M, Nakabayashi T et al.: Higher avidity binding of apolipoprotein (E-AII) complex than of apolipoprotein E monomer to β-amyloid. J. Neurosci. Res. 58(2), 301-307 (1999).
160. Brewer HB Jr, Lux SE, Ronan R et al.: Amino acid sequence of human apoLp-Gln-II (ApoA-II), an apolipoprotein isolated from the high-density lipoprotein complex. Proc. Natl Acad. Sci. USA 69(5), 1304-1308 (1972).
161. Miida T, Yamada T, Seino U et al.: Serum amyloid A (SAA)-induced remodeling of CSF-HDL. Biochim. Biophys. Acta 1761(4), 424-433 (2006).
162. Soutar AK, Naoumova RP: Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 4(4), 214-225 (2007).
163. Hobbs HH, Russell DW, Brown MS et al.: The LDL-C receptor locus in familial hyperchol-esterolemia: mutational analysis of a membrane protein. Annu. Rev. Genet. 24, 133-170 (1990).
164. Streja D, Steiner G, Kwiterovich PO Jr: Plasma high-density lipoproteins and ischemic heart disease: studies in a large kindred with familial hypercholesterolemia. Ann. Intern. Med. 89(6), 871-880 (1978).
165. Schonfeld G, Patsch W, Rudel LL et al.: Effects of dietary cholesterol and fatty acids on plasma lipoproteins. J. Clin. Invest. 69(5), 1072-1080 (1982).
166. Goldberg RB, Fless GM, Baker SG et al.: Abnormalities of high density lipoproteins in homozygous familial hypercholesterolemia. Arteriosclerosis 4(5), 472-478 (1984).
167. Ishida BY, Frolich J, Fielding CJ: Preβ-migrating high density lipoprotein: quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer. J. Lipid Res. 28(7), 778-786 (1987).
168. Ferrieres J, Lambert J, Lussier-Cacan S et al.: Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL-C receptor gene mutation. Circulation 92(3), 290-295 (1995).
169. Gibson JC, Goldberg RB, Rubinstein A et al.: Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterol-emia. Arteriosclerosis 7(4), 401-407 (1987).
170. Assmann G, Schmitz G, Menzel HJ et al.: Apolipoprotein E polymorphism and hyperlipidemia. Clin. Chem. 30(5), 641-643 (1984).
171. Leren TP, Borresen AL, Berg K et al.: Increased frequency of the apolipoprotein E-4 isoform in male subjects with multifactorial hypercholesterolemia. Clin. Genet. 27(5), 458-462 (1985).
172. Eto M, Watanabe K, Iwashima Y et al.: Increased frequency of apolipoprotein ε4 allele in type II diabetes with hypercholesterolemia. Diabetes 36(11), 1301-1306 (1987).
173. Wiegman A, Sijbrands EJ, Rodenburg J et al.: The apolipoprotein ε4 allele confers additional risk in children with familial hypercholesterolemia. Pediatr. Res. 53(6), 1008-1012 (2003).
174. Eto M, Watanabe K, Ishii K: Reciprocal effects of apolipoprotein E alleles (ε 2 and ε4) on plasma lipid levels in normolipidemic subjects. Clin. Genet. 29(6), 477-484 (1986).
175. Sing CF, Davignon J: Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37(2), 268-285 (1985).
176. Eto M, Watanabe K, Chonan N et al.: Familial hypercholesterolemia
177. de Gennes JL, Touraine R, Maunand B et al.: Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment. Bull. Mem. Soc. Med. Hop. Paris 118(15), 1377-1402 (1967).
178. Bosch T, Wendler T: State of the art of low-density lipoprotein apheresis in the year 2003. Ther. Apher. Dial. 8(2), 76-79 (2004).
179. Mabuchi H, Koizumi J, Shimizu M et al.: Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 82(12), 1489-1495 (1998).
180. Thompson GR: LDL-C apheresis. Atherosclerosis 167(1), 1-13 (2003).
181. Lund-Katz S, Laplaud PM, Phillips MC et al.: Apolipoprotein B-100 conformation and particle surface charge in human LDL-C subspecies: implication for LDL-C receptor interaction. Biochemistry 37(37), 12867-12874 (1998).
182. Davidson WS, Sparks DL, Lund-Katz S et al.: The molecular basis for the difference in charge between pre-β- and α-migrating high density lipoproteins. J. Biol. Chem. 269(12), 8959-8965 (1994).
183. Desrumaux C, Athias A, Masson D et al.: Influence of the electrostatic charge of lipoprotein particles on the activity of the human plasma phospholipid transfer protein. J. Lipid Res. 39(1), 131-142 (1998).
184. Moriarty PM: LDL-apheresis therapy: current therapeutic practice and potential future use. Future Lipidol. 1(3), 10 (2006).
185. de Ferranti SD, Rifai N: C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc. Pathol. 16(1), 14-21 (2007).
186. Ridker PM, Rifai N, Rose L et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347(20), 1557-1565 (2002).
187. Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
188. Kobayashi J, Katsube S, Shimoda M et al.: Single LDL-C apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Clin. Chim. Acta 321(1-2), 107-112 (2002).
189. Moriarty PM, Gibson CA: Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2. Am. J. Cardiol. 95(10), 1246-1247 (2005).
190. Moriarty PM, Gibson CA, Shih J et al.: C-reactive protein and other markers of inflammation among patients undergoing HELP LDL-C apheresis. Atherosclerosis 158(2), 495-498 (2001).
191. Otto C, Geiss HC, Empen K et al.: Long-term reduction of C-reactive protein concentration by regular LDL-C apheresis. Atherosclerosis 174(1), 151-156 (2004).
192. Wieland E, Schettler V, Armstrong VW: Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. Atherosclerosis 162(1), 187-191 (2002).
193. Kaul S, Jayaweera AR: Determinants of microvascular flow. Eur. Heart J. 27(19), 2272-2274 (2006).
194. Glagov S, Zarins C, Giddens DP et al.: Hemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries. Arch. Pathol. Lab. Med. 112(10), 1018-1031 (1988).
195. Crowley JP, Metzger J, Assaf A et al.: Low density lipoprotein cholesterol and whole blood viscosity. Ann. Clin. Lab. Sci. 24(6), 533-541 (1994).
196. Sloop GD, Garber DW: The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans. Clin. Sci. (Lond.) 92(5), 473-479 (1997).
197. Rosenson RS, Shott S, Tangney CC: Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis 161(2), 433-439 (2002).
198. Stamos TD, Rosenson RS: Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis 146(1), 161-165 (1999).
199. Slyper A, Le A, Jurva J et al.: The influence of lipoproteins on whole-blood viscosity at multiple shear rates. Metabolism 54(6), 764-768 (2005).
200. Ruhenstroth-Bauer G, Mossmer G, Ottl J et al.: Highly significant negative correlations between erythrocyte aggregation value and serum concentration of high density lipoprotein cholesterol in a sample from a normal population and in patients with coronary heart disease. Eur. J. Clin. Invest. 17(3), 275-279 (1987).
201. Rosenson RS, Lowe GD: Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 140(2), 271-280 (1998).
202. Grutzmacher P, Landgraf H, Esser R et al.: In vivo rheologic effects of lipid apheresis techniques: comparison of dextran sulfate LDL-C adsorption and heparin induced LDL-C precipitation. ASAIO Trans. 36(3), M327-M330 (1990).
203. Schmaldienst S, Banyai S, Stulnig TM et al.: Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis 151(2), 493-499 (2000).
204. Richter WO, Jacob BG, Ritter MM et al.: Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metab. Clin. Exp. 42(7), 888-894 (1993).
205. Parker TS, Gordon BR, Saal SD et al.: Plasma high density lipoprotein is increased in man when low density lipoprotein (LDL) is lowered by LDL-pheresis. Proc. Natl Acad. Sci. USA 83(3), 777-781 (1986).
206. Hershcovici T, Schechner V, Orlin J et al.: Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. J. Clin. Apher. 19(2), 90-97 (2004).
207. Schechner V, Berliner S, Shapira I et al.: Comparative analysis between dextran sulfate adsorption and direct adsorption of lipoproteins in their capability to reduce erythrocyte adhesiveness/aggregation in the peripheral blood. Ther. Apher. Dial. 8(1), 39-44 (2004).
208. Jackson RL, Busch SJ, Cardin AD: Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol. Rev. 71(2), 481-539 (1991).
209. Cheung MC, Albers JJ: Active plasma phospholipid transfer protein is associated with ApoA-I- but not ApoE-containing lipoproteins. J. Lipid Res. 47(6), 1315-1321 (2006).
210. Ancsin JB, Kisilevsky R: The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274(11), 7172-7181 (1999).
211. +-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. J. Biol. Chem. 262(4), 1456-1460 (1987).
212. Palumbo B, Cardinali L, Sinzinger H: LDL-apheresis removes serum amyloid P and A in hypercholesterolemic patients. Thromb. Res. 97(6), 491-494 (2000).
213. Kojima S, Harada-Shiba M, Yamamoto A: Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column. Ther. Apher. 1(4), 309-313 (1997).
214. Yoshidome H, Kuriyama M, Fujiyama J et al.: Serum amyloid A and P protein levels are lowered by dextran sulfate cellulose low-density lipoprotein apheresis. Artif. Organs 22(2), 144-148 (1998).
215. Navab M, Ananthramaiah GM, Reddy ST et al.: The double jeopardy of HDL. Ann. Med. 37(3), 173-178 (2005).
216. Opole IO, Belmont JM, Kumar A et al.: Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am. J. Cardiol. 100(9), 1416-1418 (2007).
217. Kawano M, Kuroda Y, Terao M et al.: Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis. Clin. Chim. Acta 318(1-2), 91-95 (2002).
218. Geiss HC, Bremer S, Barrett PH et al.: In vivo metabolism of LDL-C subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL-C subfractions after LDL-C apheresis. J. Lipid Res. 45(8), 1459-1467 (2004).
219. Koizumi J, Inazu A, Fujita H et al.: Removal of apolipoprotein E-enriched high density lipoprotein by LDL-apheresis in familial hypercholesterolaemia: a possible activation of the reverse cholesterol transport system. Atherosclerosis 74(1-2), 1-8 (1988).
220. Krimbou L, Tremblay M, Davignon J et al.: Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-β1-LpE, pre-β2-LpE, and α-LpE. J. Lipid Res. 38(1), 35-48 (1997).
221. Weisgraber KH, Mahley RW: Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography. J. Lipid Res. 21(3), 316-325 (1980).
222. Cardin AD, Hirose N, Blankenship DT et al.: Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem. Biophys. Res. Commun. 134(2), 783-789 (1986).
223. Crawford JG: Alzheimer's disease risk factors as related to cerebral blood flow. Med. Hypotheses 46(4), 367-377 (1996).
224. Sun ZW, Zhu YX, Liu HY et al.: Decreased cerebral blood flow velocity in apolipoprotein E ε4 allele carriers with mild cognitive impairment. Eur. J. Neurol. 14(2), 150-155 (2007).
225. Lautenschlager NT, Cox KL, Flicker L et al.: Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300(9), 1027-1037 (2008).
226. Igarashi K, Tsuji M, Nishimura M et al.: Improvement of endothelium-dependent coronary vasodilation after a single LDL-C apheresis in patients with hypercholesterolemia. J. Clin. Apher. 19(1), 11-16 (2004).
227. Sato M, Amano I: Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis. Ther. Apher. Dial. 7(4), 419-424 (2003).
228. Kobayashi K, Yamashita K, Tasaki H et al.: Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL-C apheresis. Ther. Apher. Dial. 8(5), 383-389 (2004).
229. Mellwig KP, Baller D, Gleichmann U et al.: Improvement of coronary vasodilatation capacity through single LDL-C apheresis. Atherosclerosis 139(1), 173-178 (1998).
230. 2 reactivity after heparin-mediated extracorporal LDL-C precipitation (HELP) in patients with coronary heart disease and hyperlipidemia. Stroke 30(9), 1802-1806 (1999).
231. Walzl B, Walzl M, Valetitsch H et al.: Increased cerebral perfusion following reduction of fibrinogen and lipid fractions. Haemostasis 25(3), 137-143 (1995).
232. Walzl M, Lechner H, Walzl B et al.: Improved neurological recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen. Stroke 24(10), 1447-1451 (1993)
233. Walzl M, Walzl B, Lechner H: Results of a two-month follow-up after single heparin-induced extracorporeal LDL-C precipatation in vascular disease. J. Stroke Cerebrovasc. Dis. 4(3), 4 (1994).
234. Gibson CA, Paolo AM et al.: Cognitive and emotional functions after rapid cholesterol lowering. Presented at: 111th Annual Convention of the American Psychological Association. Toronto, Canada, 8-12 August (2003).
235. Mackey RH, Kuller LH, Sutton-Tyrrell K et al.: Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. Am. J. Cardiol. 90(8A), I71-I76 (2002)
236. Rosenson RS, Otvos JD, Freedman DS: Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol. 90(2), 89-94 (2002).
237. El Harchaoui K, Arsenault BJ, Franssen R et al.: High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med. 150(2), 84-93 (2009).
238. Moriarty PM, Gibson CA: Association between hematological parameters and high-density lipoprotein cholesterol. Curr. Opin. Cardiol. 20(4), 318-323 (2005).
239. Ullrich H, Kleinjung T, Steffens T et al.: Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis. J. Clin. Apher. 19(2), 71-78 (2004).
240. Balletshofer BM, Stock J, Rittig K et al.: Acute effect of rheopheresis on peripheral endothelial dysfunction in patients suffering from sudden hearing loss. Ther. Apher. Dial. 9(5), 385-390 (2005).
241. Suckfull M: Fibrinogen and LDL-C apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 360(9348), 1811-1817 (2002).
242. Kobayashi S, Moriya H, Negishi K et al.: LDL-apheresis up-regulates VEGF and IGF-I in patients with ischemic limb. J. Clin. Apher. 18(3), 115-119 (2003).
243. Kobayashi S, Moriya H, Maesato K et al.: LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J. Clin. Apher. 20(4), 239-243 (2005).
244. Mii S, Mori A, Sakata H et al.: LDL-C apheresis for arteriosclerosis obliterans with occluded bypass graft: change in prostacyclin and effect on ischemic symptoms. Angiology 49(3), 175-180 (1998).
245. Walzl B, Walzl M, Lechner P et al.: Heparin-induced extracorporeal LDL-C precipitation (HELP), a new therapeutic intervention in cerebrovascular diseases and peripheral arterial occlusive disease. Wien. Med. Wochenschr. 143(22), 563-570 (1993).
246. Muso E, Mune M, Fujii Y et al.: Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL-C apheresis compared with steroid monotherapy. Nephron 89(4), 408-415 (2001).
247. Nakamura T, Kawagoe Y, Ogawa H et al.: Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am. J. Kidney Dis. 45(1), 48-53 (2005).
248. Ramunni A, Giancipoli G, Guerriero S et al.: LDL-apheresis accelerates the recovery of nonarteritic acute anterior ischemic optic neuropathy. Ther. Apher. Dial. 9(1), 53-58 (2005).
249. Friedman DS, O'Colmain BJ, Munoz B et al.: Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122(4), 564-572 (2004).
250. Pulido JS: Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans. Am. Ophthalmol. Soc. 100, 85-106; discussion 106-107 (2002).
251. Wang Y, Walli AK, Schulze A et al.: Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus. Apher. Sci. 35(2), 103-110 (2006).